Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | Director | March 18, 2026 | March 18, 2026 |
| ChemoCentryx, Inc.CCXI · Entity 122928 | Chief Operating Officer | January 03, 2018 | January 05, 2018 |
| Frazier Life Sciences Acquisition Corp. IIFLSC · Entity 184069 | Director | October 13, 2026 | October 13, 2026 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| Rein Therapeutics, Inc.RNTX · Entity 7071 | Director | July 23, 2025 | July 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,117 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,117 F1: Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $102.70 · Expires 2032-09-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrants vested 25% on September 13, 2023 and thereafter in 36 equal monthly installments. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: Each restricted stock unit represents a contingent right to receive one ADS. F3: The restricted stock units vest on March 1, 2027 and have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Each restricted stock unit represents a contingent right to receive one ADS. F5: The restricted stock units vest in two equal annual installments beginning on March 1, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: Each restricted stock unit represents a contingent right to receive one ADS. F6: The restricted stock units vest in three equal annual installments beginning on March 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
F2: The warrants vested 25% on September 13, 2023 and thereafter in 36 equal monthly installments.
F3: The restricted stock units vest on March 1, 2027 and have no expiration date.
F4: Each restricted stock unit represents a contingent right to receive one ADS.
F5: The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
F6: The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
ChemoCentryx, Inc.
Report date January 03, 2018 · Filed January 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2028-01-03 | Direct | 575,000 |
Reported balance
After 2018-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-03 · Grant · Acquired 575,000 · Balance 575,000 F2: Not applicable. F1: The option was granted on January 3, 2018. 25% of the total number of shares of common stock subject to the option will vest on January 3, 2019, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 3, 2018. 25% of the total number of shares of common stock subject to the option will vest on January 3, 2019, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F2: Not applicable.
Frazier Life Sciences Acquisition Corp. II
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Rein Therapeutics, Inc.
Report date July 23, 2025 · Filed July 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2035-07-22 | Direct | 17,500 |
Reported balance
After 2025-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-23 · Grant · Acquired 17,500 · Balance 17,500 F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KalVista Pharmaceuticals, Inc.
Report date June 11, 2026 · Filed June 11, 2026
Section 16 reporting ended · disclosed 2026-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2034-04-17 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option vests over a 36 month period: 1/36th on May 18, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.54 · Expires 2034-10-02 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F4: The option vests over a 12 month period: 1/12th on November 3, 2024, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05 · Expires 2035-09-30 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F5: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").
F2: The option vests over a 36 month period: 1/36th on May 18, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.
F4: The option vests over a 12 month period: 1/12th on November 3, 2024, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.
F5: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.
MyoKardia, Inc.
Report date November 17, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 1
1 source rowRow 1 · 2020-11-17 · Other · Disposed 42,199 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.99 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-17 · Disposition to issuer · Disposed 69,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-17 · Disposition to issuer · Disposed 39,022 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantDeferred Stock Units · Derivative | 1,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001727275-26-000004 · form4-06172026_080609.xml · derivative · entry 2 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 3,772 | $0.00 Strike: $101.00 | $0.00 |
DisclosureSEC source: 0001727275-26-000004 · form4-06172026_080609.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,772 Underlying: Common Stock · 3,772 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:38 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $12.05 | Not disclosed |
DisclosureSEC source: 0001727275-26-000002 · form4-06112026_080646.xml · derivative · entry 3 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-09-30 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F5 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:38 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $11.54 | Not disclosed |
DisclosureSEC source: 0001727275-26-000002 · form4-06112026_080646.xml · derivative · entry 2 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2034-10-02 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F4 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 3, 2024, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:38 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001727275-26-000002 · form4-06112026_080646.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2034-04-17 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option vests over a 36 month period: 1/36th on May 18, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 22:29 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001727275-25-000003 · form4-10022025_101036.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| July 23, 2025 Filed Jul 23, 2025 23:37 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000950170-25-098041 · ownership.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-07-22 F1 · derivative.exercise_date: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 3,203 | $48.42 | $155,090.54 |
DisclosureSEC source: 0001415889-25-017188 · form4-06132025_080649.xml · nonDerivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:35 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantDeferred Stock Units · Derivative | 3,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015302 · form4-06022025_110622.xml · derivative · entry 4 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,977 Underlying: Common Stock · 3,977 shares Expires not disclosed F4 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F4 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F4 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:35 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 6,268 | $0.00 Strike: $44.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015302 · form4-06022025_110622.xml · derivative · entry 3 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,268 Underlying: Common Stock · 6,268 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:35 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015302 · form4-06022025_110622.xml · derivative · entry 2 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · derivative.exercise_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:35 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 5,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015302 · form4-06022025_110622.xml · nonDerivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| December 02, 2024 Filed Dec 6, 2024 21:35 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000950170-24-134153 · ownership.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-01 F1 · derivative.exercise_date: This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest in full on December 2, 2025. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:08 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001415889-24-024753 · form4-10042024_081042.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The option vests over a 12-month period: 1/12th on November 3, 2024, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:06 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-099837 · ownership.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-08-19 F1 · derivative.exercise_date: This option was granted on August 20, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) August 20, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:19 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016063 · form4-06072024_100607.xml · derivative · entry 2 Fairey William · CIK 0001727275 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,703 Underlying: Common Stock · 5,703 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:19 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 8,779 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001415889-24-016063 · form4-06072024_100607.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,779 Underlying: Common Stock · 8,779 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 20:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001415889-24-011319 · form4-04222024_080443.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-04-17 F1 · derivative.exercise_date: The option vests over a 36 month period: 1/36th on May 18, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 00:55 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 5,450 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0000899243-23-020117 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,450 Underlying: Common Stock · 5,450 shares Expires 2033-10-30 F1 · derivative.exercise_date: This option was granted October 31, 2023. The shares underlying the option are scheduled to vest over 48 equal monthly installments from October 31, 2023, subject to continued service. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:47 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001209191-23-037129 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2024 annual stockholder meeting. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 22:03 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 12,750 | $0.00 Strike: $23.51 | $0.00 |
DisclosureSEC source: 0001209191-22-034641 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 12,750 shares Expires 2032-06-01 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 21:17 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001209191-21-052805 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-08-18 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:20 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 39,022 | Not disclosed Strike: $70.40 | Not disclosed |
DisclosureSEC source: 0000899243-20-031757 · doc4.xml · derivative · entry 3 Fairey William · CIK 0001727275 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,022 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:20 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 69,500 | Not disclosed Strike: $40.99 | Not disclosed |
DisclosureSEC source: 0000899243-20-031757 · doc4.xml · derivative · entry 2 Fairey William · CIK 0001727275 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,500 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:20 UTC | MyoKardia, Inc. MYOK · Entity 145206 | OtherCommon Stock | 42,199 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031757 · doc4.xml · nonDerivative · entry 1 Fairey William · CIK 0001727275 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 20:37 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 12,598 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-005179 · doc4.xml · derivative · entry 2 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,598 Underlying: Common Stock · 12,598 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 20:37 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 39,022 | $0.00 Strike: $70.40 | $0.00 |
DisclosureSEC source: 0000899243-20-005179 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,022 Underlying: Common Stock · 39,022 shares Expires 2030-02-13 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 3, 2020 20:55 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionRestricted Stock Units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002644 · doc4.xml · derivative · entry 3 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 Underlying: Common Stock · 8,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 3, 2020 20:55 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 2,899 | $68.04 | $197,247.96 |
DisclosureSEC source: 0000899243-20-002644 · doc4.xml · nonDerivative · entry 2 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,226 F2 · shares: Represents the number of shares of Issuer's Common Stock sold to cover the Reporting Person's withholding taxes in connection with the vesting of 8,125 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 01, 2020 Filed Feb 3, 2020 20:55 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 8,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002644 · doc4.xml · nonDerivative · entry 1 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:27 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002654 · doc4.xml · derivative · entry 2 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units shall vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units shall vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The units shall vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:27 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 69,500 | $0.00 Strike: $40.99 | $0.00 |
DisclosureSEC source: 0000899243-19-002654 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,500 Underlying: Common Stock · 69,500 shares Expires 2029-01-31 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the option on February 1, 2020 and in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 19:45 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy · Derivative | 575,000 | Not disclosed Strike: $6.19 | Not disclosed |
DisclosureSEC source: 0001209191-18-002575 · doc4.xml · derivative · entry 1 Fairey William · CIK 0001727275 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2028-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2018. 25% of the total number of shares of common stock subject to the option will vest on January 3, 2019, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.